Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05973773 · ClinicalTrials.gov registry record · Phase 3
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
A Phase 3 study of Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, sponsored by Taiho Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 285
- Enrollment target
- 20
- Study locations
NCT05973773 is a Phase 3 study of Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation that is active but no longer recruiting, run by Taiho Oncology. The registered enrollment target is 285 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT05973773, a Phase 3 study of Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, is active but no longer recruiting, sponsored by Taiho Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 285 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Conditions Studied
Interventions
- DRUG TAS6417
Study Locations (20)
Nevada
- Comprehensive Cancer Centers of Nevada - Henderson - Henderson
- Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson - Henderson
- Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie - Henderson
- Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II - Las Vegas
- Comprehensive Cancer Centers of Nevada - Southwest - Las Vegas
- Comprehensive Cancer Centers of Nevada - Central Valley - Twain - Las Vegas
- Comprehensive Cancer Centers of Nevada - Northwest - Las Vegas
Rio Grande do Sul
- Hospital Mãe de Deus - Centro Integrado de Oncologia - Porto Alegre
- Hospital São Lucas da PUCRS - Porto Alegre
Ohio
- Gabrail Cancer and Research Center - Canton
Texas
- University of Texas MD Anderson Cancer Center - Houston
Flemish Brabant
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg - Leuven
Oost-Vlaaderen
- Algemeen Ziekenhuis Maria Middelares - Ghent
West Flanders
- Algemeen Ziekenhuis Delta - Campus Menen - Menen
West-Vlaanderen
- Algemeen Ziekenhuis Delta - Campus Rumbeke - Rosières
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2027-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05973773
The ClinicalTrials.gov registry entry for NCT05973773 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation appearing as the primary indexed condition, and to 1 intervention - of which TAS6417 is the first listed.
NCT05973773 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Nevada, Rio Grande do Sul, Ohio.
Frequently Asked Questions
What is clinical trial NCT05973773 about?
NCT05973773 is a clinical study titled "REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)". The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
What is the current status of trial NCT05973773?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 285 participants. The study started on 2023-12-18. Estimated completion is 2027-05-27.
What conditions does trial NCT05973773 study?
This clinical trial studies the following conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation.
What interventions are being tested in trial NCT05973773?
The interventions under investigation include: TAS6417 (DRUG).
Who is sponsoring clinical trial NCT05973773?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05973773 being conducted?
This trial has 20 study locations across Nevada, Ohio, Texas, Flemish Brabant, Oost-Vlaaderen. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.